Hereditary Angioedema Therapeutic Market Trends and Forecast
The future of the global hereditary angioedema therapeutic market looks promising with opportunities in the hospital and clinic markets. The global hereditary angioedema therapeutic market is expected to grow with a CAGR of 5.1% from 2025 to 2031. The major drivers for this market are the increasing awareness about hereditary angioedema treatments, the rising demand for personalized therapeutic solutions, and the growing focus on improving patient care outcomes.
• Lucintel forecasts that, within the type category, subcutaneous is expected to witness the highest growth over the forecast period.
• Within the application category, hospital is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Hereditary Angioedema Therapeutic Market
Emerging trends are reshaping the hereditary angioedema therapeutic market by focusing on more convenient, effective, and long-lasting treatments. These trends are moving the industry towards a more patient-centric approach to care, with an emphasis on preventing HAE attacks rather than just treating them. The goal is to provide patients with greater control over their condition and a better quality of life.
• Shift to Prophylactic Treatment: A significant trend is the move from on-demand, acute treatment to long-term prophylactic therapies. The impact is a dramatic reduction in the frequency and severity of HAE attacks. This shift allows patients to live more normal lives, reducing hospital visits and the unpredictable nature of the disease, which is a key driver for market growth.
• Growth of Oral Therapies: The market is seeing a trend toward the development of oral medications for both on-demand and prophylactic use. The impact is a huge improvement in patient convenience and adherence. An oral pill is much easier to administer than an injection, making it a highly attractive option for patients who prefer non-invasive treatments and greater independence.
• Development of Subcutaneous Injections: There is an increasing trend for self-administered subcutaneous therapies, often using a pre-filled pen or autoinjector. The impact is a move towards home-based care. These treatments give patients the ability to manage their condition at home, avoiding frequent visits to clinics and providing them with greater flexibility and control.
• Focus on Next-Generation Therapies: The market is seeing a trend towards a new class of therapies, such as monoclonal antibodies and small interfering RNA (siRNA) treatments. The impact is a more targeted and effective treatment with a longer duration of action. These therapies work by targeting specific proteins in the disease pathway, offering a powerful and innovative approach to managing HAE.
• Increasing Role of Diagnostics: A key trend is the integration of advanced diagnostics and genetic testing for HAE. The impact is earlier and more accurate diagnosis. By identifying HAE patients more quickly, they can begin treatment sooner, which is crucial for preventing life-threatening attacks and improving long-term health outcomes.
These emerging trends are fundamentally reshaping the hereditary angioedema therapeutic market by transforming it from a reactive to a proactive model of care. The focus has shifted to developing patient-centric, convenient, and highly effective long-term prophylactic therapies, which is not only driving market growth but also empowering patients to lead fuller, healthier lives.
Recent Development in the Hereditary Angioedema Therapeutic Market
Recent developments in the hereditary angioedema therapeutic market are focused on improving patient outcomes and quality of life through innovative, convenient, and effective treatment options. These developments are centered on new drug approvals, advanced delivery methods, and a deeper understanding of the diseaseÄX%$%Xs underlying mechanisms. The goal is to provide a comprehensive range of therapies that cater to different patient needs and preferences.
• Approval of Novel Therapies: Recent developments include the approval of new, targeted therapies. The impact is an expansion of the treatment landscape for HAE. These new drugs, particularly long-acting prophylactic treatments, offer a powerful new tool for preventing attacks and provide patients with a greater sense of security and control over their condition.
• Advancements in Self-Administration: A key development is the introduction of user-friendly self-administration devices for subcutaneous therapies. The impact is improved patient convenience and adherence. Devices like pre-filled pens and autoinjectors simplify the injection process, allowing patients to administer their medication at home, thereby reducing the burden of frequent clinic visits.
• Rise of Oral Prophylaxis: The market has seen a recent development in the launch of once-daily oral therapies. The impact is a major shift in patient preference towards non-invasive treatment. The convenience of a pill has proven highly attractive to patients, leading to a significant uptake and challenging the dominance of injectable treatments.
• Pipeline of Gene Therapies: Recent developments include a growing pipeline of gene-based therapies and gene editing candidates. The impact is a potential one-time cure for HAE. While still in early clinical stages, these revolutionary treatments aim to correct the underlying genetic defect, offering the potential to permanently resolve the condition and eliminate the need for ongoing medication.
• Strategic Partnerships & Acquisitions: The market is seeing a development in strategic partnerships and acquisitions among pharmaceutical companies. The impact is an acceleration of R&D and market expansion. For instance, the acquisition of Shire by Takeda has consolidated key HAE assets, creating a major player with a comprehensive portfolio of therapies and a global reach.
These developments are having a profound impact on the hereditary angioedema therapeutic market by accelerating the transition to a more patient-centric model of care. The focus on convenience, efficacy, and potentially curative therapies is not only driving market growth but also offering unprecedented hope and improved quality of life for HAE patients worldwide.
Strategic Growth Opportunities in the Hereditary Angioedema Therapeutic Market
Strategic growth opportunities in the hereditary angioedema therapeutic market are concentrated on expanding the use of these therapies across a wider patient population and for different stages of the disease. These opportunities capitalize on the unique needs of HAE patients and the potential of new technologies to provide more convenient, effective, and long-lasting treatments. The focus is on leveraging innovation to address unmet clinical needs.
• Long-term Prophylaxis: The greatest growth opportunity lies in the long-term prophylaxis segment. The impact is a substantial improvement in patient quality of life and a reduction in healthcare costs associated with acute attacks. As patients and physicians increasingly favor prevention over on-demand treatment, this segment is expected to see a significant and sustained increase in adoption.
• Oral Treatments for New Patients: A key strategic opportunity is targeting new or previously undiagnosed HAE patients with convenient oral therapies. The impact is a dramatic expansion of the patient base. The ease of a pill can overcome the barrier of needle-phobia and the inconvenience of injections, making it an ideal first-line therapy for those newly diagnosed with HAE.
• Combination and Adjunctive Therapies: There is a growth opportunity in developing therapies that can be used in combination with existing treatments. The impact is enhanced efficacy and a more personalized approach to care. For patients who do not respond fully to a single therapy, a combination approach could offer a more effective solution, addressing a significant unmet need.
• Pediatric HAE Market: The pediatric HAE market represents a strategic growth opportunity, as many current therapies have age restrictions. The impact is an earlier intervention and a healthier childhood for patients. Developing safe and effective treatments for children is a priority, as early management can prevent disease progression and improve long-term outcomes.
• Emerging Market Penetration: Penetrating emerging markets with cost-effective and accessible therapies is a long-term growth opportunity. The impact is a significant increase in the global patient population receiving treatment. With rising healthcare spending and growing awareness in regions like China and India, there is a large, underserved patient population that represents a key area for future market expansion.
These strategic growth opportunities are reshaping the hereditary angioedema therapeutic market by diversifying its applications and integrating it into a broader global healthcare landscape. The focus on new patient populations, convenient delivery methods, and preventive care is driving market innovation and positioning HAE therapies as a critical area of growth in rare disease management.
Hereditary Angioedema Therapeutic Market Driver and Challenges
Major drivers and challenges impacting the hereditary angioedema therapeutic market are a complex interplay of technological, economic, and regulatory factors. These forces are influencing market growth and shaping the competitive landscape. While the increasing prevalence of the disease and advancements in targeted therapies are propelling the market forward, issues related to high treatment costs, misdiagnosis, and a lack of access pose significant hurdles.
The factors responsible for driving the hereditary angioedema therapeutic market include:
1. Rising Prevalence of HAE: The increasing incidence of hereditary angioedema globally is a primary driver. This growing patient pool creates a pressing need for effective therapeutic solutions, fueling research and development efforts and ensuring a sustained demand for both on-demand and prophylactic treatments to manage the disease.
2. Technological Advancements in Drug Development: Significant advancements in biotechnology have led to the development of highly targeted and effective therapies. This is a major driver as new treatments, such as kallikrein inhibitors and monoclonal antibodies, offer superior efficacy and more convenient administration, leading to better patient outcomes and higher market adoption.
3. Growing Patient and Physician Awareness: Increased awareness of HAE among both patients and healthcare professionals is a key driver. This heightened knowledge leads to earlier and more accurate diagnosis, which in turn increases the number of patients seeking treatment, thereby expanding the market and creating a demand for a wider range of therapeutic options.
4. Shift Towards Prophylactic Treatment: The market is driven by a growing preference for prophylactic, or preventive, therapies over on-demand treatments. This shift is a major driver, as long-term prevention is seen as a more effective strategy for improving patient quality of life and reducing the number of life-threatening HAE attacks.
5. Supportive Government Policies: Favorable government policies, such as the Orphan Drug Act in the U.S. and similar initiatives in other countries, are a key driver. These policies provide incentives for companies to develop treatments for rare diseases, leading to a robust pipeline of new therapies and accelerating their path to market.
Challenges in the hereditary angioedema therapeutic market are:
1. High Cost of Treatment: The significant cost of HAE therapies, especially for long-term prophylactic treatments, is a major challenge. The high price point can be a barrier for patients and healthcare systems, limiting access to these life-changing medications and creating a significant affordability issue.
2. Diagnostic Delays and Misdiagnosis: HAE is a rare disease, and a lack of awareness among general practitioners often leads to diagnostic delays and misdiagnosis. This challenge results in a large number of undiagnosed patients who are not receiving proper treatment, which can lead to severe health consequences and limits the marketÄX%$%Xs full potential.
3. Limited Access in Developing Regions: A key challenge is the limited access to advanced HAE therapies in developing regions due to a lack of specialized healthcare infrastructure and high costs. This creates a significant disparity in care, with a large, underserved patient population that is unable to benefit from the latest treatments available in developed countries.
The overall impact of these drivers and challenges is a market that is expanding, but with significant constraints. While the demand for effective therapies and a robust pipeline are creating a strong impetus for growth, issues of cost, diagnosis, and access are creating a competitive and sometimes restrictive environment. The marketÄX%$%Xs future will depend on its ability to address these hurdles through innovation, strategic pricing, and global outreach.
List of Hereditary Angioedema Therapeutic Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hereditary angioedema therapeutic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hereditary angioedema therapeutic companies profiled in this report include-
• BioCryst Pharma
• Ionis Pharma
• Pharming Group
• CSL Limited
• Shire
• Attune Pharma
• Adverum Biotechnologies
Hereditary Angioedema Therapeutic Market by Segment
The study includes a forecast for the global hereditary angioedema therapeutic market by type, application, and region.
Hereditary Angioedema Therapeutic Market by Type [Value from 2019 to 2031]:
• Intravenous
• Subcutaneous
• Oral
Hereditary Angioedema Therapeutic Market by Application [Value from 2019 to 2031]:
• Hospitals
• Clinics
• Others
Hereditary Angioedema Therapeutic Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Hereditary Angioedema Therapeutic Market
The hereditary angioedema therapeutic market is a dynamic sector driven by a growing understanding of this rare genetic disorder and the development of new, targeted therapies. Recent advancements are focused on improving patient quality of life by offering more convenient, effective, and long-lasting treatment options. This shift is moving the market from on-demand, acute care to proactive, long-term prophylaxis.
• United States: The U.S. market is a global leader, characterized by a robust pipeline of new therapies and strong reimbursement policies. Recent developments include the approval of novel oral and subcutaneous prophylactic treatments, giving patients more convenient alternatives to intravenous injections. This focus on long-term prevention is significantly improving patient quality of life.
• China: China’s market is rapidly growing, with recent developments centered on expanding access to HAE therapies. The government is supporting the diagnosis of rare diseases, and there are a growing number of local and international collaborations. TakedaÄX%$%Xs Takhzyro, for example, received approval in China in 2020, marking a significant step in providing advanced treatment options to the region.
• Germany: In Germany, the market is defined by strong national guidelines and a focus on patient-centric care for rare diseases. Developments include the establishment of specialized HAE centers to provide expert care. The market is seeing an increasing adoption of long-term prophylactic therapies, driven by a commitment to improving patient outcomes and quality of life.
• India: The Indian market is in its early stages but is seeing growth propelled by increasing awareness and government support for rare diseases. The National Policy for Rare Diseases offers financial assistance, which helps patients access treatments. Recent developments are focused on improving diagnostic capabilities and increasing the availability of both local and imported HAE therapies.
• Japan: JapanÄX%$%Xs market is technologically advanced and has a high level of patient awareness. Developments include the approval and commercialization of innovative HAE therapies, such as the licensing of new investigational therapies. The market is also driven by a strong presence of key pharmaceutical companies like Takeda, which is a major player in the HAE therapeutic landscape.
Features of the Global Hereditary Angioedema Therapeutic Market
Market Size Estimates: Hereditary angioedema therapeutic market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Hereditary angioedema therapeutic market size by type, application, and region in terms of value ($B).
Regional Analysis: Hereditary angioedema therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the hereditary angioedema therapeutic market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hereditary angioedema therapeutic market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for hereditary angioedema therapeutic market?
Answer: The global hereditary angioedema therapeutic market is expected to grow with a CAGR of 5.1% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the hereditary angioedema therapeutic market?
Answer: The major drivers for this market are the increasing awareness about hereditary angioedema treatments, the rising demand for personalized therapeutic solutions, and the growing focus on improving patient care outcomes.
Q3. What are the major segments for hereditary angioedema therapeutic market?
Answer: The future of the hereditary angioedema therapeutic market looks promising with opportunities in the hospital and clinic markets.
Q4. Who are the key hereditary angioedema therapeutic market companies?
Answer: Some of the key hereditary angioedema therapeutic companies are as follows:
• BioCryst Pharma
• Ionis Pharma
• Pharming Group
• CSL Limited
• Shire
• Attune Pharma
• Adverum Biotechnologies
Q5. Which hereditary angioedema therapeutic market segment will be the largest in future?
Answer: Lucintel forecasts that, within the type category, subcutaneous is expected to witness the highest growth over the forecast period.
Q6. In hereditary angioedema therapeutic market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the hereditary angioedema therapeutic market by type (intravenous, subcutaneous, and oral), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Hereditary Angioedema Therapeutic Market, Hereditary Angioedema Therapeutic Market Size, Hereditary Angioedema Therapeutic Market Growth, Hereditary Angioedema Therapeutic Market Analysis, Hereditary Angioedema Therapeutic Market Report, Hereditary Angioedema Therapeutic Market Share, Hereditary Angioedema Therapeutic Market Trends, Hereditary Angioedema Therapeutic Market Forecast, Hereditary Angioedema Therapeutic Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.